PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18615588-0	2008	Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency.	Valproic Acid	0-13	methylenetetrahydrofolate reductase	Mus musculus	38-73	
18615588-0	2008	Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency.	Valproic Acid	0-13	methylenetetrahydrofolate reductase	Mus musculus	75-80	
18615588-0	2008	Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency.	Valproic Acid	0-13	methylenetetrahydrofolate reductase	Mus musculus	118-123	
18615588-5	2008	Mthfr(+/+) mice had increased resorption rates (36%) after VPA treatment, compared to saline treatment (10%), whereas resorption rates were similar in Mthfr(+/-) mice with the two treatments (25-27%).	Valproic Acid	59-62	methylenetetrahydrofolate reductase	Mus musculus	0-5	
18615588-8	2008	Consistent with cellular MTHFR upregulation by VPA, brain MTHFR enzyme activity was increased and plasma homocysteine was decreased in VPA-treated pregnant mice compared to saline-treated animals.	Valproic Acid	47-50	methylenetetrahydrofolate reductase	Mus musculus	25-30	
18615588-8	2008	Consistent with cellular MTHFR upregulation by VPA, brain MTHFR enzyme activity was increased and plasma homocysteine was decreased in VPA-treated pregnant mice compared to saline-treated animals.	Valproic Acid	135-138	methylenetetrahydrofolate reductase	Mus musculus	25-30	
18615588-8	2008	Consistent with cellular MTHFR upregulation by VPA, brain MTHFR enzyme activity was increased and plasma homocysteine was decreased in VPA-treated pregnant mice compared to saline-treated animals.	Valproic Acid	135-138	methylenetetrahydrofolate reductase	Mus musculus	58-63	
18065414-8	2008	Transfection of c-Jun and two activators of c-Jun (LiCl and sodium valproate) increased MTHFR expression, whereas a reported inhibitor of c-Jun (SP600125) and a dominant-negative derivative of c-Jun N-terminal kinase-1 reduced MTHFR activation.	Valproic Acid	60-76	methylenetetrahydrofolate reductase	Mus musculus	88-93